Tackling the challenge
Our team at CanSense is composed of award-winning expertise, bringing together scientists, clinicians and business on the major challenge of early diagnosis of cancer. Our world-leading team is delivering a technological breakthrough in cancer diagnostics by implementing cutting edge spectroscopy innovation with advanced AI analytics for early stage cancer diagnosis.
As a team we importantly deliver unique clinical and market insights which are focussed on bringing change to patient outcomes, drug development and healthcare provision.
Adam Bryant CEO & Director
Adam has spent the last 20 years in investment banking, working in a variety of positions in London tier 1 institutions. Most recently he was Head of Macro Products at UBS and part of the Senior Management team in Fixed Income at CS.
Adam spent most of his career as a senior Managing Director, creating dynamic, highly sophisticated teams, covering the largest Global Hedge Funds and Real Money Asset Managers in Fixed Income. Last year he turned his attention to his passion of combining technology with business and worked as an Executive Chairman of a Blockchain Startup company.
He is an active adviser and investor, specialising in financial services and technology in the startup arena. He holds a PhD in Theoretical Physics from UWCC and has presented at various Parliamentary APPG meetings on Fintech and Blockchain.
Dean Harris Founder & Director
Dean was appointed as a consultant colorectal surgeon in Swansea in 2010 (Swansea Bay University Health Board) and is an honorary professor in Swansea University Medical School.
His busy colorectal cancer practice in Swansea positions him well to understand the current challenges of early cancer diagnosis. He subspecialises in advanced rectal cancer providing tertiary surgical services to the patients of Wales through working within the Swansea Pelvic Oncology Group. He has contributed to international guidelines and opinion in this field. He also performs microsurgical techniques for early rectal cancer and is a proficient laparoscopic surgeon and therapeutic colonoscopist. He has interests in genetic colorectal cancer management and is actively involved in cancer pathway redesign projects.
He is an enthusiastic researcher and surgical trainer and has published over 50 peer reviewed papers and has given 30 invited lectures to date. He is currently a Wales Cancer Research Centre Clinical Research Leader and was awarded the MediWales Innovation Awards for Research Excellence in 2016 for his work on Raman spectroscopy in clinical practice.
He has attracted over £1 million in grant funding towards clinical utility of Raman spectroscopy as an early colorectal cancer diagnostic tool and as a diagnostic adjunct in primary care. Along with Professor Peter Dunstan he co-leads the Biospectroscopy research group in Swansea.
Peter Dunstan Founder & Director
Peter is a professor of Physics at Swansea University. An award-winning physicist, he has over 25 years of experience in experimental physics, with specific leading expertise in spectroscopy and bio-spectroscopy. Peter was one of the key academic research leads in the formation of the Centre for Nanohealth (CNH) at Swansea, a major £21.6M project started in 2009.
Peter is currently Science Director of the Centre and has published over 45 peer-reviewed publications whilst being the primary supervisor for sixteen PhD students to date. Peter also has extensive collaborative experience delivering on funded research programmes with industrial partners.
It was within the CNH arena that the initial meeting and collaboration between Peter and Professor Dean Harris began in 2013, and together they have established a successful Biospectroscopy group which has attracted over £1M of research funding.
Cerys Jenkins Founder & Director
Cerys is a dynamic researcher with a strong interdisciplinary background with experience in physics, chemistry and medical research. Her main research focus is on early cancer diagnostics using spectroscopic techniques combined to AI. Cerys has over five years of experience in clinical spectroscopy, during which time she gained her PhD.
Cerys developed methodologies behind the CanSense Ltd technology during her PhD within Swansea’s Biospectroscopy group working alongside Professors Dean Harris and Peter Dunstan. The work is award winning, recently she won the Herald Scotland Global Game Changers Women in Innovation award 2018.
Cerys has attracted over £850k in project team funding as a co-investigator and published peer-reviewed papers.